U.S. Markets close in 5 hrs 35 mins
  • S&P 500

    4,437.78
    +81.33 (+1.87%)
     
  • Dow 30

    34,727.63
    +429.90 (+1.25%)
     
  • Nasdaq

    13,885.21
    +345.92 (+2.55%)
     
  • Russell 2000

    2,037.51
    +33.48 (+1.67%)
     
  • Crude Oil

    87.06
    +1.46 (+1.71%)
     
  • Gold

    1,834.00
    -18.50 (-1.00%)
     
  • Silver

    23.88
    -0.02 (-0.09%)
     
  • EUR/USD

    1.1289
    -0.0017 (-0.1468%)
     
  • 10-Yr Bond

    1.7890
    +0.0060 (+0.34%)
     
  • Vix

    28.91
    -2.25 (-7.22%)
     
  • GBP/USD

    1.3501
    -0.0005 (-0.0351%)
     
  • USD/JPY

    114.3510
    +0.4850 (+0.4259%)
     
  • BTC-USD

    38,309.25
    +2,135.95 (+5.90%)
     
  • CMC Crypto 200

    880.65
    +24.83 (+2.90%)
     
  • FTSE 100

    7,521.85
    +150.39 (+2.04%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ICPT, BSX and QIWI

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • ICPT
  • BSX
  • BSX-PA
  • QIWI

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Class Period: September 28, 2019 - October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint alleges that throughout the class period Intercept Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Defendants downplayed the true scope and severity of safety concerns associated with the use of Ocaliva (obeticholic acid ("OCA")), Intercept's lead product candidate, in treating primary biliary cholangitis; (ii) the foregoing increased the likelihood of a U.S. Food and Drug Administration ("FDA") investigation into Ocaliva's development, thereby jeopardizing Ocaliva's continued marketability and the sustainability of its sales; (iii) any purported benefits associated with OCA's efficacy in treating nonalcoholic steatohepatitis ("NASH") were outweighed by the risks of its use; (iv) as a result, the FDA was unlikely to approve the Company's New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (v) as a result of all the foregoing, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ICPT: http://www.kleinstocklaw.com/pslra-1/intercept-pharmaceuticals-inc-loss-submission-form?id=11920&from=1

Boston Scientific Corporation (NYSE:BSX)
Class Period: April 24, 2019 - November 16, 2020
Lead Plaintiff Deadline: February 2, 2021

The BSX lawsuit alleges Boston Scientific Corporation made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in BSX: http://www.kleinstocklaw.com/pslra-1/boston-scientific-corporation-loss-submission-form-2?id=11920&from=1

Qiwi plc (NASDAQ:QIWI)
Class Period: March 28, 2019 - December 9, 2020
Lead Plaintiff Deadline: February 9, 2021

Throughout the class period, Qiwi plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Qiwi's internal controls related to reporting and record-keeping were ineffective; (2) consequently, the Central Bank of Russia would impose a monetary fine upon the Company and impose restrictions upon the Company's ability to make payments to foreign merchants and transfer money to pre-paid cards; and (3) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Learn about your recoverable losses in QIWI: http://www.kleinstocklaw.com/pslra-1/qiwi-plc-loss-submission-form?id=11920&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/623019/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ICPT-BSX-and-QIWI